Account wins from the 06/06/06 News Brief

Share this article:
Seidler Bernstein is developing an international marketing and communications program for Dako’s Serum HER-2/neu, a biomarker assay for metastatic breast cancer assessment. Seidler Bernstein's Dako account creative team will include Jennifer Vaughan, account manager; Alla Litovchenko, senior designer; and Rob Kinslow, copywriter. GSW Worldwide has been named agency of record for telavancin in the United States.  Telavancin is a lipoglycopeptide injectable antibiotic currently in Phase 3 studies for the treatment of complicated skin and skin structure infections and hospital-acquired pneumonia. Discovered by Theravance, telavancin is being co-developed worldwide with Astellas Pharma. Once approved by the FDA, GSW Worldwide will provide a broad range of strategic marketing and promotional services for telavancin in the US. The account will be based in GSW Worldwide's Columbus office. Duramed Pharmaceuticals has retained Pace, part of Lowe Healthcare Worldwide, as consumer and professional agency for the relaunch of ParaGard (intrauterine copper contraceptive). Duramed acquired ParaGard when it bought FEI Women's Health last year for $281.5 million. MBL Communications has appointed independent media representative company Sherburne Medical Media to represent various accounts for the publications CNS Spectrums and Primary Psychiatry and for Psychiatry Weekly.
Share this article:

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.